Ubs Group Ag Portage Biotech Inc. Transaction History

Ubs Group Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.21 - $0.55 $1,180 - $3,091	5,620 Added 158.85%	9,158 $1,000
Q1 2024 May 13, 2024	BUY	$0.41 - $1.89 $1,409 - $6,497	3,438 Added 3438.0%	3,538 $1,000
Q3 2023 Nov 09, 2023	SELL	$2.09 - $3.68 $535 - $942	-256 Reduced 71.91%	100 $0
Q2 2023 Aug 11, 2023	SELL	$2.73 - $3.87 $1,575 - $2,232	-577 Reduced 61.84%	356 $1,000
Q1 2023 May 12, 2023	BUY	$2.6 - $7.2 $171 - $475	66 Added 7.61%	933 $2,000
Q4 2022 Feb 08, 2023	BUY	$4.42 - $150.6 $3,390 - $115,510	767 Added 767.0%	867 $4,000
Q3 2022 Nov 10, 2022	SELL	$6.81 - $136.4 $12,366 - $247,702	-1,816 Reduced 94.78%	100 $1,000
Q2 2022 Aug 10, 2022	BUY	$5.16 - $11.95 $4,128 - $9,560	800 Added 71.68%	1,916 $14,000
Q1 2022 May 16, 2022	SELL	$6.57 - $12.0 $6,182 - $11,292	-941 Reduced 45.75%	1,116 $8,000
Q4 2021 Feb 14, 2022	BUY	$10.73 - $23.74 $16,545 - $36,607	1,542 Added 299.42%	2,057 $23,000
Q3 2021 Nov 15, 2021	SELL	$13.65 - $22.4 $57,234 - $93,923	-4,193 Reduced 89.06%	515 $10,000
Q2 2021 Aug 13, 2021	BUY	$20.96 - $42.81 $98,679 - $201,549	4,708 New	4,708 $99,000

28.4K

Ticker PRTG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,943,700
Market Cap $83M
Description
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a smal...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.